{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Monotherapy", "query": { "condition": "Monotherapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1370, "total_pages": 137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Monotherapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:38:53.696Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05734066", "title": "Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Ewing Sarcoma", "Relapsed Ewing Sarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 60, "start_date": "2023-05-23", "completion_date": "2028-04-20", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05734066" }, { "nct_id": "NCT01218100", "title": "Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Stage 2 Diastolic Hypertension" ], "interventions": [ { "name": "nebivolol and lisinopril (free combination)", "type": "DRUG" }, { "name": "nebivolol monotherapy", "type": "DRUG" }, { "name": "lisinopril monotherapy", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 664, "start_date": "2010-10", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-06-21", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 89, "location_summary": "Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218100" }, { "nct_id": "NCT03019003", "title": "Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Oral Decitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "5' Azacitidine", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-03-20", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019003" }, { "nct_id": "NCT00071253", "title": "Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Divalproex Sodium (Delayed-Release Tablets)", "type": "DRUG" }, { "name": "Divalproex Sodium (Extended-Release Tablets)", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 180, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-08-04", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 15, "location_summary": "Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "North Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071253" }, { "nct_id": "NCT01243177", "title": "Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy", "Monotherapy" ], "interventions": [ { "name": "Lacosamide", "type": "DRUG" }, { "name": "Carbamazepine-Controlled Release", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 888, "start_date": "2011-04", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 15, "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243177" }, { "nct_id": "NCT03257631", "title": "A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasms", "Medulloblastoma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 53, "start_date": "2017-09-18", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 6, "location_summary": "Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257631" }, { "nct_id": "NCT07241039", "title": "A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Squamous Tumors" ], "interventions": [ { "name": "ABBV-711", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2025-11-20", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07241039" }, { "nct_id": "NCT03477175", "title": "Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "E7080", "type": "DRUG" }, { "name": "Comparator Drug", "type": "DRUG" }, { "name": "Comparator Drug: Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-16", "completion_date": "2023-12-21", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 3, "location_summary": "Torrance, California • Chicago, Illinois • Detroit, Michigan", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03477175" }, { "nct_id": "NCT02788279", "title": "A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2016-07-05", "completion_date": "2018-12-26", "has_results": true, "last_update_posted_date": "2019-12-11", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 17, "location_summary": "Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788279" }, { "nct_id": "NCT00300456", "title": "Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemia", "Coronary Heart Disease", "Mixed Dyslipidemia" ], "interventions": [ { "name": "ABT-335", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2006-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2009-06-03", "last_synced_at": "2026-05-21T23:38:53.696Z", "location_count": 1, "location_summary": "North Chicago, Illinois", "locations": [ { "city": "North Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300456" } ] }